Search

Your search keyword '"Giannini, EDOARDO GIOVANNI"' showing total 251 results

Search Constraints

Start Over You searched for: Author "Giannini, EDOARDO GIOVANNI" Remove constraint Author: "Giannini, EDOARDO GIOVANNI"
251 results on '"Giannini, EDOARDO GIOVANNI"'

Search Results

1. Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study

3. Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part II – Non-surgical treatments

4. Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part I – Surgical treatments

5. Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis

7. Are Small Molecules Effective in Treating Inflammatory Pouch Disorders Following Ileal Pouch-Anal Anastomosis for Ulcerative Colitis? Here Is Where We Stand.

9. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.

14. Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part I – Surgical treatments

16. Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis

18. The Italian data on SARS-CoV-2 infection in transplanted patients support an organ specific immune response in liver recipients

19. Prophylaxis of HBV-recurrence after liver transplantation in patients with HCC: risk of HCC recurrence from a large, multicentre retrospective study from Italy

20. Feasibility of systemic anti-cancer therapy as an alternative to best supportive care in patients with advanced HCC and Child-Pugh B liver dysfunction

21. RESIST criteria accurately rule-out high-risk esophageal varices in patients with primary biliary cholangitis and compensated advanced chronic liver disease

22. Long-term real-world experience with obeticholic acid in primary biliary cholangitis: the Italian recapitulate study

23. Development and validation of a score predicting response to obeticholic acid in primary biliary cholangitis: the OCA response score (ORS)

24. Food Intolerances, Food Allergies and IBS: Lights and Shadows.

25. Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria

29. Usefulness of longitudinal assessment of AFP in DAA cured HCV cirrhotic patients to predict the developmente of HCC

30. Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study

32. Predictors of serious adverse events and non‐response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid.

33. Therapeutic drug monitoring in Crohn’s disease patients treated with anti-TNF: a comparison of two techniques

34. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience

35. Prevention Strategies for Esophageal Cancer—An Expert Review

36. Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data

37. Vonoprazan fumarate for the treatment of gastric ulcers: A short review on emerging data

38. THU-134 - Feasibility of systemic anti-cancer therapy as an alternative to best supportive care in patients with advanced HCC and Child-Pugh B liver dysfunction

39. WED-260 - RESIST criteria accurately rule-out high-risk esophageal varices in patients with primary biliary cholangitis and compensated advanced chronic liver disease

40. OS-069 - Prophylaxis of HBV-recurrence after liver transplantation in patients with HCC: risk of HCC recurrence from a large, multicentre retrospective study from Italy

41. OS-070 - Development and validation of a score predicting response to obeticholic acid in primary biliary cholangitis: the OCA response score (ORS)

42. OS-045 - Long-term real-world experience with obeticholic acid in primary biliary cholangitis: the Italian recapitulate study

46. Alphafetoprotein and Transplant Survival Benefit for Patients with Hepatocellular Carcinoma: A Multicentre Cohort Study.: Abstract# O-122

47. Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis

48. Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma

49. Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis

50. Is global score better than a single histological parameter for assessing microscopic esophagitis?

Catalog

Books, media, physical & digital resources